IRVINE, Calif., Dec. 16, 2013 /PRNewswire/ -- EP Global
Communications, Inc., (OTC Ticker EPGL) makes the following
announcement:
In a first for the company, one of EPGL's advanced technologies
has been selected by a multi-billion dollar, NYSE publicly traded
industry leader for development and integration into new
products.
The Development Agreement was signed last week, being the week
of December 8, 2013.
"This is the biggest development for our company in its
history," said David T. Markus PhD. "This is just the
first of many possible Agreements to come for EPGL and its advanced
technologies. EPGL is a leader in BioMEMS technology and the
companies we develop with will become leaders as well in this field
for their particular products."
The two companies have signed a confidentiality agreement due to
the sensitive and competitive nature of the technology.
Details of the first Development Agreement will remain confidential
for now. However, PwC as custodian for AJW Funds Board
membership of EPGL has been apprised of the Agreement and its
details.
EPGL currently has over 15 new advanced technologies and
corporations in the medical device and consumer electronics fields
have sought to enter relationship with the company. Because
of this development, EPGL intends to expand upon and focus on this
business model going forward.
EPGL Management and Team would like to wish all of our
shareholders a Merry Christmas, Happy Hanukkah and Happy New Year.
About EP Global Communications, Inc.
EP Global Communications, Inc. is an advanced technology
development company for both medical devices and consumer
electronics. EPGL also holds an FDA 510k cleared medical
device called the MPD1. The MPD1 is a revolutionary new diagnostic
and therapeutic tool for the muscular originated pain in the human
body.
Safe Harbor Statement
Certain matters discussed in this press release are
"forward-looking statements" intended to qualify for the safe
harbors from liability established by the Private Securities
Litigation Reform Act of 1995. In particular, the Company's
statements regarding trends in the marketplace and potential future
results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties,
including, but not limited to, the timing of projects due to the
variability in size, scope and duration of projects, estimates made
by management with respect to the Company's critical accounting
policies, regulatory delays, clinical study results which lead to
reductions or cancellations of projects, and other factors,
including general economic conditions and regulatory developments,
not within the Company's control. The factors discussed herein and
expressed from time to time in the Company's filings with the
Securities and Exchange Commission could cause actual results and
developments to be materially different from those expressed in or
implied by such statements. The forward-looking statements are made
only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
SOURCE EP Global Communications, Inc.